Where does Dyne Therapeutics, Inc. rank among US patent assignees?

According to USPTO PatentsView (2015–2025 granted utility patents), Dyne Therapeutics, Inc. ranks #6,643 of 49,997 assignees by granted-patent volume, the same sort as the companies listing and top-holders ranking. See /methodology/#corpus-placement.

How many patents does Dyne Therapeutics, Inc. hold?

Dyne Therapeutics, Inc. holds 50 US utility patents granted between 2021 and 2025, spanning 5 technology areas.

What is Dyne Therapeutics, Inc.'s Innovation Score?

Dyne Therapeutics, Inc. has an Innovation Score of 56.1 out of 100 (top 6% of the corpus). This composite metric weighs portfolio volume (40%), grant velocity (20%), technology breadth (25%), and claim depth (15%).

What technology areas does Dyne Therapeutics, Inc. focus on?

Dyne Therapeutics, Inc.'s top technology area is C07K (Peptides) with 49 patents, ranking #183 of 3,615 assignees active in that subclass. Grants appear in 5 CPC subclasses total.

Is Dyne Therapeutics, Inc.'s patent grant rate increasing or decreasing?

Insufficient historical data is available to calculate a velocity trend for Dyne Therapeutics, Inc..

What does claim depth mean for Dyne Therapeutics, Inc.'s patents?

Dyne Therapeutics, Inc.'s patents average 24.4 claims each. This is an aggregate descriptive count from the grant record; it does not establish claim scope, legal strength, enforceability, or design-around risk.

How is the Dyne Therapeutics, Inc. patent data sourced?

All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.

USPTO 2015–2025 USPTO PatentsView US Corporation

Dyne Therapeutics, Inc.

USPTO PatentsView assignee record - 50 granted patents across 5 technology areas, recorded in grant years 2021–2025. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: C07K (Peptides).

Compiled by PlainPatent · May 15, 2026

RSS updates for this company

Explore the portfolio See the ranking

The verdict

According to USPTO PatentsView, Dyne ranks #6,643 of 49,997 tracked US assignees by granted-patent volume, with 50 patents across 5 technology areas.

#6,643
of 49,997 US assignees by volume: Top 6%
by Innovation Score (56.1/100): 24.4
avg claims per patent

USPTO PatentsView assignee plate

Corpus R6643 · US Corporation #6,643 · 50 grants

GRANTS-SMALL · UPPER-Q · PHOTO-FINISH · CPC-NARROW · INNOV-PAR · CLAIMS-DENSE · TYPE-USCORP · SPAN-YRS · BOOK-RICH

GRANTS-SMALL 50 grants
UPPER-Q #6,643/49,997
PHOTO-FINISH Cytiva BioProcess…
CPC-NARROW C07K · 5 areas
INNOV-PAR 56.1/100
CLAIMS-DENSE 24.4 claims/avg
TYPE-USCORP US Corporation
SPAN-YRS 2021–2025 · 5y
BOOK-RICH 9/10 fields

Nearest grant-volume peer: Cytiva BioProcess R&D AB (±0 grants)

Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.

How Dyne’s 56.1 Innovation Score adds up

The same four weighted components behind every Innovation Score on PlainPatent: portfolio volume, grant velocity, technology breadth, and claim depth.

Volume 13.6 pts (24%) Velocity 20.0 pts (36%) Breadth 7.9 pts (14%) Claim depth 14.6 pts (26%)

Qualcomm Incorporated · highest

85
Ball · near

56
BenQ · near

56
Dyne Therapeutics · this assignee

56
Workaround · near

56
THE Queen's… · near

56
3D Lighting… · lowest

7

What this shows Dyne's Innovation Score is 56.1/100 (top 6% of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.

Does more volume mean deeper claims for Dyne?

Each dot is one of Dyne’s 8 nearest volume peers (same corpus rank neighbourhood as the chart above), placed by total granted patents (horizontal) against average claims per patent (vertical). Dyne’s own 24.4 claims/patent is ABOVE the 16.0 median for these volume peers. More thorough claims than most filers at this scale, not just more of them.

Dyne vs its 8 nearest volume peers: granted patents vs average claims per patent. Source: USPTO PatentsView.

Where Dyne's grants concentrate

Dyne Therapeutics, Inc. is a focused PatentsView assignee: 5 CPC subclasses with 98% of grants classified under C07K (Peptides). Peak complete grant year is 2023 (15 grants) versus a trough of 2 in 2021. By volume, Dyne sits between Cytiva BioProcess R&D AB and Focaltech Systems Co., Ltd..

Dyne's three-year grant acceleration

Dyne Therapeutics, Inc. shows 35 grants in 2022–2024 against only 2 in 2019–2021. That prior window is too thin for a growth multiple (rename and spin-out assignees look artificially high when the baseline is near zero), so PlainPatent withholds a ranked acceleration claim here.

Cytiva Bioprocess…

50
Daiki

50
Dana Motion Syste…

50
Damaka

50
European Space Ag…

50
F5

50
Fluid Handling

50
Focaltech Systems

50
Dyne Therapeutics ◀

50

What this shows Dyne holds 50 patents at rank #6,643, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Companies ranked near Dyne

By rank, the assignees closest to #6,643 in granted patent volume.

Leaders in C07K (Peptides)

Other assignees with the most granted patents in Dyne's primary technology class.

Assignees with similar portfolio profiles

Two PlainPatent-derived peer sets for Dyne, neither rank-band nor same-CPC leaders (those blocks stay above). In C07K (Peptides), Dyne ranks #183 of 3,615 assignees by patent count in that subclass.

Similar innovation score

Nearest assignees by Innovation Score (56 here).

BenQ Corporation 56 Ball Corporation 56 Workaround GMBH 56 THE Queen's University OF Belfast 56

Similar claim depth

Nearest assignees by average claims per patent (24.4 here).

Howard Hughes Medical Institute 24.4 avg Cognitive Systems Corp. 24.4 avg Gigamon Inc. 24.4 avg Immunogen, Inc. 24.4 avg

Dyne's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

56 Top 6% higher than 94% of 49,997 US assignees

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

USPTO utility patent grants by year · 2021–2025

Grants by year

Teal-shaded recent years (2020–present) versus the 2021–2019 baseline. Full figures in the table below.

View data table

Dyne Therapeutics, Inc. patent grants by year, 2015–2025
Year	Patents Granted	Share of Period
2021	2	4.0%
2022	6	12.0%
2023	15	30.0%
2024	14	28.0%
2025partial year	13	26.0%

Which technologies does Dyne Therapeutics, Inc. patent most?

C07K - Peptides 49

A61K - Preparations FOR Medical, Dental OR Toiletry Purposes 49

C12N - Microorganisms OR ENZYMES; Compositions THEREOF; Propagating, Preserving, OR Maintaining MICROORGANISMS; Mutation OR Genetic ENGINEERING; Culture Media 40

A61P - Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations 39

C12Y - Enzymes 12

Top 5 of 5 technology areas

More on this record

Data Source

USPTO PatentsView, US granted patents 2015–2025

View all rankings → How is Innovation Score calculated?

What to do with this data

Dyne Therapeutics, Inc.'s patent record in context - here's where to go next.

Dyne Therapeutics, Inc.'s lead technology class is C07K (Peptides), 98% of its portfolio - see every assignee active in that class. Explore C07K
Ranked #6,643 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
Compare Dyne Therapeutics, Inc. against Cytiva BioProcess R&D AB, an assignee filing at a similar volume. Compare portfolios
Innovation Score of 56.1/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated

Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.

Data sourced from USPTO PatentsView - official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

Data sources used on this page

USPTO PatentsView - the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
Cooperative Patent Classification (CPC) - the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
USPTO Patent Public Search - the official interface to verify the status of any individual patent. ppubs.uspto.gov

Compiled by PlainPatent, US Patent Intelligence Editorial Process · May 15, 2026

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.